Nouveaux Pharma Limited
Public pharmaceutical company · Karachi · Pakistan
Nouveaux Pharma Limited, formerly Novartis Pharma (Pakistan) Limited, is a Karachi-based pharmaceutical company focused on innovative and specialty therapies.
What is sourced, and how recent is it?
Regulatory-source portfolio data and company-supplied/corporate profile fields are tracked separately. Company claim/verification status is separate from source quality. An unclaimed company can still have a fully official-source-observed portfolio.
Company profile
- Company type
- Public pharmaceutical company
- Address
- 15 West Wharf Road, West Wharf, Karachi, Pakistan
- Website
- nplpk.com ↗
- Phone
- +92 21 32313386
- Corporate source details checked
- 16 Aug 2026
- Corporate profile completeness
- 88%
Company location
A sourced company location is recorded. Use the map link below for directions.
Portfolio at a glance
RegistrationA unique regulatory registration number. One registration may have more than one strength/form/pack presentation.
PresentationA distinct medicine presentation, such as a particular strength, dosage form and pack.
IndexedA canonical MedInfoBase presentation that passed MedInfoBase identity and publication controls.
Source observedAn additional presentation observed in an official DRAP source but not counted as an indexed MedInfoBase presentation.
Registry onlyAn exact registry-verified registration not otherwise represented by an indexed or source-observed presentation.
Registry verifiedAn exact registration match found in an official DRAP registry source. This is evidence status, not a commercial ranking.
How complete is this profile?
Downloadable company intelligence charts
Copy or download any chart as a presentation-ready PNG. Every exported chart keeps MedInfoBase attribution and the source company-profile URL.
Therapeutic Portfolio Mix
Shows where the company portfolio is concentrated across broad therapeutic areas.
Portfolio distribution, not sales or market-share data.
Dosage Form Portfolio
Shows how the company portfolio is distributed across tablets, capsules, injections, liquids and other forms.
Counts are product presentations, not production or sales volumes.
Equivalent Price Position
Shows whether safely comparable products are below, near or above the peer median unit price.
This is price-position intelligence, not sales, demand or market-share data.
Closest Portfolio Competitors
Highlights other manufacturers with the greatest generic overlap with this company portfolio.
Competitor ranking is based on shared generics in MedInfoBase, not commercial sales performance.
Therapeutic areas
High-level clinical areas represented by this company’s current MedInfoBase portfolio.
Drug classes
More specific classes derived from the canonical generic and preserved curated classifications.
Dosage forms
How MedInfoBase classifies the portfolio
MedInfoBase uses a two-level taxonomy. Therapeutic area is a broad portfolio category, while drug class is the more specific pharmacological or clinical class. Existing curated classifications are preserved. Blank records are assigned conservatively from the canonical generic name and, when available, ATC information. Multi-use medicines may be placed in a cross-therapeutic category rather than forced into a single indication.
Deepest brand families
Unit-price positioning vs equivalent products
How MedInfoBase calculates price position
Only current prices with safely interpretable pack quantities are used. A product is compared only with the same generic, same stated strength, same dosage form and a compatible unit basis such as tablet, capsule, mL or gram. These are database-derived price comparisons, not sales or market-share estimates.
Portfolio overlap
Companies sharing the largest number of generics with this portfolio. This measures product overlap, not commercial performance.
Observed database signals
These dates describe records observed by MedInfoBase. They should not be interpreted as product launch dates or sales activity.
Medicine portfolio
This unified portfolio keeps three evidence lanes distinct: indexed MedInfoBase presentations, additional source-observed presentations, and registry-only registrations that are not otherwise represented. A registration number is not the same thing as a presentation, and source-observed rows are not counted as indexed. Source-only rows with a strength/form/pack contradiction remain visible as evidence but the conflicting field is held for normalization.
| Brand | Generic | Strength | Form | Pack | Registration | Source-listed price | Unit price | Price position |
|---|---|---|---|---|---|---|---|---|
| Afinitor | Everolimus | 5 mg | Tablet | 30's | 069519 | PKR 708,006.70 | PKR 23,600.22/tablet | 1,038% above median |
| Afinitor | Everolimus | 10 mg | Tablet | 30's | 069520 | PKR 1,011,438.15 | PKR 33,714.61/tablet | 961% above median |
| Certican | Everolimus | 0.25 mg | Tablet | 60's | 044829 | PKR 19,385.90 | PKR 323.10/tablet | 43% above median |
| Certican | Everolimus | 0.75 mg | Tablet | 60's | 044830 | PKR 53,853.46 | PKR 897.56/tablet | 59% above median |
| Ciloxan | Ciprofloxacin | 0.3% | Ophthalmic drops | 5 ml | 091913 | PKR 455.43 | PKR 91.09/mL | 160% above median |
| Desferal | Deferoxamine mesylate (desferrioxamine) | 500 mg | Powder for solution for injection/infusion | 10's | 001958 | PKR 5,532.54 | PKR 553.25/vial/unit | No comparator |
| Femara | Letrozole | 2.5 mg | Tablet | 30's | 021129 | PKR 19,089.35 | PKR 636.31/tablet | 59% above median |
| Glivec | Imatinib | 100 mg | Tablet | 60's | 033196 | PKR 144,571.29 | PKR 2,409.52/tablet | 124% above median |
| Glivec | Imatinib | 400 mg | Tablet | 30's | 033197 | PKR 289,142.58 | PKR 9,638.09/tablet | 180% above median |
| Mepresor | Metoprolol Tartrate | 100 mg | Tablet | 3x10 | 007823 | PKR 487.37 | PKR 16.25/tablet | 45% above median |
| Oleptiss | Deferasirox | 90 mg | Tablet | 30's | 091901 | PKR 5,816.73 | PKR 193.89/tablet | No comparator |
| Oleptiss | Deferasirox | 180 mg | Tablet | 30's | 091902 | PKR 9,695.85 | PKR 323.20/tablet | 6% above median |
| Oleptiss | Deferasirox | 360 mg | Tablet | 30's | 091903 | PKR 16,159.11 | PKR 538.64/tablet | 6% above median |
| Sandimmun | Ciclosporin | 250 mg/5 mL (50 mg/mL) | Concentrate for solution for IV infusion | 10 x 5ml | 008008 | PKR 10,301.78 | PKR 206.04/mL | No comparator |
| Sandimmun | Ciclosporin | 100 mg/mL | Oral solution | 50 ml | 014961 | PKR 21,781.89 | PKR 435.64/mL | 61% above median |
| Sandimmun | Ciclosporin | 100 mg | Capsule | 50's | 014962 | PKR 21,781.89 | PKR 435.64/capsule | 45% above median |
| Sandimmun | Ciclosporin | 25 mg | Capsule | 50's | 014963 | PKR 5,446.20 | PKR 108.92/capsule | 45% above median |
| Sandostatin | Octreotide | 0.1 mg | Injection | 5's | 115716 | PKR 6,809.38 | PKR 1,361.88/vial/unit | 69% above median |
| Sandostatin | Octreotide | 0.05 mg | Injection | 5's | 115717 | PKR 3,415.17 | PKR 683.03/vial/unit | No comparator |
| Sandostatin LAR | Octreotide | 10 mg | Injection | 1's | 027323 | PKR 131,798.95 | PKR 131,798.95/vial/unit | No comparator |
| Sandostatin LAR | Octreotide | 20 mg | Long-acting depot injection | 1's | 027324 | PKR 171,145.26 | PKR 171,145.26/vial/unit | No comparator |
| Sandostatin LAR | Octreotide | 30 mg | Long-acting depot injection | 1's | 027325 | PKR 237,754.57 | PKR 237,754.57/vial/unit | No comparator |
| Seebri Breezhaler | Glycopyrronium | 50 mcg | Inhalation capsule | 30's | 078111 | PKR 11,177.98 | PKR 372.60/capsule | No comparator |
| Tasigna | Nilotinib | 200 mg | Capsule | 28's | 052256 | PKR 226,923.17 | PKR 8,104.40/capsule | 160% above median |
| Tasigna | Nilotinib | 200 mg | Capsule | 112's | 052256 | PKR 907,692.67 | PKR 8,104.40/capsule | 160% above median |
| Tasigna | Nilotinib | 150 mg | Capsule | 40's | 072543 | PKR 243,131.97 | PKR 6,078.30/capsule | 154% above median |
| Tasigna | Nilotinib | 150 mg | Capsule | 112's | 072543 | PKR 680,769.50 | PKR 6,078.30/capsule | 154% above median |
| Tasigna | Nilotinib | 150 mg | Capsule | 120's | 072543 | PKR 729,395.90 | PKR 6,078.30/capsule | 154% above median |
| Tasigna | Nilotinib | 50 mg | Capsule | 28's | 105591 | PKR 72,754.47 | PKR 2,598.37/capsule | Near median |
| Tasigna | Nilotinib | 50 mg | Capsule | 112's | 105591 | PKR 291,015.02 | PKR 2,598.35/capsule | Near median |
| Tegral | Carbamazepine | 200 mg | Tablet | 50's | 021529 | PKR 540.84 | PKR 10.82/tablet | Near median |
| Tegral | Carbamazepine | 100 mg/5 mL | Oral solution | 100 ml | 070803 | PKR 143.54 | PKR 1.44/mL | No comparator |
| Tegral | Carbamazepine | 100 mg | Tablet | 50's | 079917 | PKR 204.47 | PKR 4.09/tablet | No comparator |
| Tegral | Carbamazepine | 400 mg | Tablet | 50's | 079918 | PKR 567.96 | PKR 11.36/tablet | 37% below median |
| Tobrex | Tobramycin | 3 mg/mL | Ophthalmic drops | 5ml | 097352 | PKR 389.27 | PKR 77.85/mL | No comparator |
| Zometa | Zoledronic acid | 4 mg | Powder for solution for infusion | 1's | 027365 | PKR 37,956.12 | PKR 37,956.12/vial/unit | No comparator |
| Zometa | Zoledronic acid | 4 mg/100 mL | Solution for infusion | 1's | 072551 | PKR 33,275.75 | PKR 33,275.75/vial/unit | Near median |
MedInfoBase company-intelligence methodology
This page is generated from MedInfoBase medicine, generic, company, price and official-source records. Unverified third-party discovery records are retained internally for coverage auditing and are not published as company registrations. Portfolio leaders are ranked by presentation depth, not sales. Price-position metrics are calculated from current official-source prices normalized to compatible units and compared only against like-for-like products with the same generic, stated strength and dosage form.
Not currently included: sales volume, revenue by brand, market share, prescription volume or best-selling rankings. MedInfoBase will display those only when supported by a defensible licensed, public or company-verified source.
Cite this record
Manufacturer recordRecords change over time. Please cite the access date so readers can locate the version you used.